113 related articles for article (PubMed ID: 38640419)
1. Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
3. The diffusion of docetaxel in patients with metastatic prostate cancer.
Unger JM; Hershman DL; Martin D; Etzioni RB; Barlow WE; LeBlanc M; Ramsey SR
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25540245
[TBL] [Abstract][Full Text] [Related]
4. The Cost of Metastatic Prostate Cancer in the United States.
Olsen TA; Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2023 Jan; 10(1):41-47. PubMed ID: 37103444
[TBL] [Abstract][Full Text] [Related]
5. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
7. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
8. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
9. Locally advanced prostate cancer: a population-based study of treatment patterns.
Lowrance WT; Elkin EB; Yee DS; Feifer A; Ehdaie B; Jacks LM; Atoria CL; Zelefsky MJ; Scher HI; Scardino PT; Eastham JA
BJU Int; 2012 May; 109(9):1309-14. PubMed ID: 22085255
[TBL] [Abstract][Full Text] [Related]
10. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
11. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.
Nambudiri VE; Landrum MB; Lamont EB; McNeil BJ; Bozeman SR; Freedland SJ; Keating NL
Urology; 2012 Mar; 79(3):537-45. PubMed ID: 22245306
[TBL] [Abstract][Full Text] [Related]
12. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
13. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
Golan R; Bernstein AN; Gu X; Dinerman BF; Sedrakyan A; Hu JC
Cancer; 2018 May; 124(10):2212-2219. PubMed ID: 29579318
[TBL] [Abstract][Full Text] [Related]
14. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
15. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
Zeliadt SB; Potosky AL; Etzioni R; Ramsey SD; Penson DF
Urology; 2004 Dec; 64(6):1171-6. PubMed ID: 15596192
[TBL] [Abstract][Full Text] [Related]
16. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
Doshi JA; Jahnke J; Raman S; Puckett JT; Brown VT; Ward MA; Li P; Manz CR
J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
[No Abstract] [Full Text] [Related]
17. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Long-Term Prescription Opioid Use Among Older Adults in the United States: A Study of Medicare Administrative Claims Data.
Ramachandran S; Salkar M; Bentley JP; Eriator I; Yang Y
Pain Physician; 2021 Jan; 24(1):31-40. PubMed ID: 33400426
[TBL] [Abstract][Full Text] [Related]
20. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.
Ellis SD; Chen RC; Dusetzina SB; Wheeler SB; Jackson GL; Nielsen ME; Carpenter WR; Weinberger M
J Oncol Pract; 2016 Apr; 12(4):e423-36. PubMed ID: 26957641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
